Development of functional ingredients derived from natural products and functional foods
First written in FY2016. 24 of 33 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2017: 1 of 9 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「For elastin, we continued research into its effects on the skin, blood vessels, joints and other areas and advanced the acquisition of new evidence related to skin claims. In addition, notifications for foods with function claims related to discomfort in the knee joints and vascular elasticity, compliant with PRISMA 2020, were accepted. For hishi extract, we continued research into its health benefits arising from its potent antiglycation activity and other properties, advanced the acquisition of evidence regarding its efficacy against frequent urination, and had a notification for a food with function claims related to urination accepted. In addition, we launched “Boke Extract,” made from quince fruit, as a new ingredient and are advancing research into its functionality related to dementia prevention.」
Notifications for foods with function claims using elastin and hishi extract were accepted, and research results progressed toward claims and commercialization, including the launch of the new ingredient Boke Extract. - 2026-05-15AdvancedEarnings presentation
「４月にハラール認証取得、タイ向けエラスチンが販売好調 脳機能改善素材「ボケエキス」25年10月上市」
機能性素材について、ハラール認証取得、タイ向けエラスチンの販売好調、新素材の上市を記載している。 - FY2025AdvancedAnnual report
「For elastin, we are conducting joint research with a university on its effects on the skin, blood vessels and joints and have obtained a patent related to the functionality of a novel peptide. For hishi extract, we are continuing research into its health benefits arising from its potent antiglycation activity and advanced the acquisition of evidence for new claims. For Ascophyllan HS, we are continuing research and development related to the prevention of infectious diseases and antitumor effects arising from its immunostimulatory activity, and advanced development for new applications.」
A patent for the functionality of a novel peptide was obtained for elastin, while research for new claims and applications is progressing for hishi extract and Ascophyllan HS. - FY2025-H1Decline in overseas elastin salesAnnual report
「In functional ingredients, revenue decreased due in part to lower overseas sales volume of elastin.」
Overseas sales volume of elastin decreased, changing the previous trend of continued increases in overseas sales. - FY2024AdvancedAnnual report
「For elastin, we are conducting joint research with a university on its effects on the skin, blood vessels and joints and have obtained a patent related to joints. For hishi extract, we are continuing research into its health benefits arising from its potent antiglycation activity, have obtained evidence of its effects on hair growth promotion and measures against frequent urination, respectively, and submitted the findings to academic journals.」
A patent related to joints was obtained for elastin, while evidence related to hair growth promotion and measures against frequent urination was obtained and submitted for hishi extract. Meanwhile, overseas sales volume of elastin decreased. - FY2024-Q3Decline in overseas elastin salesAnnual report
「In functional food ingredients, revenue decreased due in part to lower overseas sales volume of elastin, a functional ingredient.」
The previous description of increasing overseas sales volume of elastin changed, with the current quarter showing declines in both sales volume and revenue. - FY2024-Q2AdvancedAnnual report
「In functional food ingredients, revenue increased due in part to higher overseas sales volume of elastin, a functional ingredient.」
Overseas sales volume of elastin, a functional ingredient, and revenue continue to increase. - FY2024-Q1RestatedAnnual report
「In the food business, revenue increased due to price revisions to address higher raw material prices and an increase in overseas sales volume of elastin, a functional ingredient, among other factors.」
The increase in overseas sales volume of elastin, a functional ingredient, and revenue continues to be reported. - FY2023AdvancedAnnual report
「For elastin, we are conducting joint research with a university on its effects on the skin and blood vessels and have obtained a patent related to skin beautification. For hishi extract, we are continuing research into its health benefits arising from its potent antiglycation activity and have obtained patents related to hair growth promotion and measures against metabolic syndrome, respectively.」
Patents were obtained for skin beautification using elastin and for hair growth promotion and measures against metabolic syndrome using hishi extract, giving concrete form to the research results for functional ingredients. - FY2023-Q3RestatedAnnual report
「In functional foods, revenue increased as overseas sales volume of elastin, a functional food ingredient, rose.」
The increase in overseas elastin sales volume and revenue continues to be reported. - FY2023-Q2AdvancedAnnual report
「In functional foods, revenue increased as overseas sales volume of elastin, a functional food ingredient, rose.」
The increase in overseas elastin sales volume and revenue is described as specific progress. - FY2022AdvancedAnnual report
「For elastin, filing research results and other evidence with the Consumer Affairs Agency under the Foods with Function Claims labeling system enabled claims concerning vascular effects, including "maintaining vascular suppleness" and "maintaining vascular flexibility," and skin effects, including "maintaining skin elasticity" and "protecting skin moisture."」
Filing with the Consumer Affairs Agency enabled functional claims concerning blood vessels and skin for elastin. Evidence accumulation and presentation of results also continued for Hishi extract and Ascophyllan. - FY2022-Q3RestatedAnnual report
「Although sales volumes of functional food ingredients and soft foods for older people increased, sales volumes of fish-paste products declined due to lower exports.」
Sales volumes of functional food ingredients and soft foods for older people continued to increase, but fish-paste products declined due to lower exports. - FY2022-Q2RestatedAnnual report
「In functional foods, sales volumes of functional food ingredients and the soft food Sofmeat for older people increased.」
Sales volumes of functional food ingredients and Sofmeat continued to increase. - FY2022-Q1AdvancedAnnual report
「Although exports of functional food ingredients increased, sales volumes of fish-paste products declined from the same period of the previous year as stay-at-home demand eased somewhat. As a result, revenue was ¥5,118 million, compared with ¥5,998 million in the same period of the previous year, falling below the previous fiscal year's level. In terms of earnings, segment profit (operating profit) was ¥96 million, up 43.2% year on year, partly due to higher sales of functional food ingredients.」
Exports and sales of functional food ingredients increased, and segment profit in the functional foods business increased 43.2% year on year. - FY2021AdvancedAnnual report
「For Ascophyllan HS, research focused on effects on immune function has continued, and the Company obtained a patent, No. 6854613, for the prevention and treatment of infectious pneumonia, titled "Composition for the Prevention and Treatment of Infectious Pneumonia."」
For Ascophyllan HS, the Company continued research into immune function and obtained a patent related to the prevention and treatment of infectious pneumonia. - FY2021-Q2Lower revenue in functional foods due to decreased exports to ChinaAnnual report
「In functional foods, revenue decreased due to lower exports to China.」
The previous trend of expanding functional food sales changed, with revenue declining in the quarter due to lower exports to China. - FY2021-Q1Lower sales volume of functional food ingredientsAnnual report
「In the Fisheries and Functional Foods Business, revenue decreased despite higher sales volumes of fish-paste products, due in part to lower sales volumes of the functional food ingredient Katsuo Elastin.」
The previous trend of expanding sales of functional food-related products changed, with Katsuo Elastin sales volume declining in the quarter and the business posting lower revenue. - FY2020AdvancedAnnual report
「For elastin, the Company filed with the Consumer Affairs Agency its research results and evidence concerning bonito-derived elastin peptides. As a result, 2 additional products became eligible to state the function of supporting knee joint movement and alleviating mild discomfort.」
The Company filed with the Consumer Affairs Agency concerning bonito-derived elastin peptides, enabling 2 additional products to make functional claims. - FY2020-Q3AdvancedAnnual report
「In the Fisheries Food Business, revenue increased due to higher sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people, as well as increased exports of fish-paste products to China. As a result, revenue was ¥3,668 million, up 2.9% year on year, and segment profit (operating profit) was ¥326 million, up 34.0% year on year.」
Higher sales of Katsuo Elastin and Sofmeat and increased exports of fish-paste products to China drove a 2.9% year-on-year increase in revenue in the Fisheries Food Business, while segment profit increased 34.0%. - FY2020-Q2AdvancedAnnual report
「In functional foods, revenue increased due to higher sales of the functional food ingredient Katsuo Elastin, Japanese confectionery and the soft food Sofmeat for older people.」
Continued sales growth of functional food-related products, including Katsuo Elastin and Sofmeat, contributed to higher revenue in the functional foods business. - FY2019AdvancedAnnual report
「For elastin, elastin peptides derived from bonito were accepted for the first time under the Consumer Affairs Agency's Foods with Function Claims labeling system, allowing claims that the product supports knee joint movement and alleviates mild discomfort.」
A specific research and commercialization advance was reported: bonito-derived elastin peptides were accepted for the first time under the Foods with Function Claims labeling system. - FY2019-Q3AdvancedAnnual report
「In the Fisheries Food Business, revenue increased as sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people remained strong. As a result, revenue was ¥3,565 million, up 1.4% year on year.」
Strong sales of Katsuo Elastin and Sofmeat continued, and revenue in the Fisheries Food Business increased 1.4% year on year. - FY2019-Q2AdvancedAnnual report
「In functional foods, revenue increased as sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people remained strong.」
Strong sales of Katsuo Elastin and Sofmeat continued, contributing to higher revenue in functional foods. - FY2019-Q1AdvancedAnnual report
「In the Fisheries Food Business, revenue increased due to strong sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people, as well as increased exports of fish-paste products. As a result, revenue was ¥1,219 million, up 4.6% year on year.」
Strong sales of Katsuo Elastin and Sofmeat continued, and together with increased exports of fish-paste products, drove a 4.6% year-on-year increase in revenue in the Fisheries Food Business. - FY2018-Q3AdvancedAnnual report
「In the Marine Food Business, revenue increased due to higher exports of fish paste products and increased sales volumes of the functional food ingredient bonito elastin and the soft food “Sofmeat” for the elderly. As a result, revenue was ¥3,515 million, up 12.7% year on year, and segment profit (operating profit) was ¥280 million, compared with ¥23 million in the same period of the previous year.」
Continued growth in sales volumes of the natural-product-derived functional ingredient Katsuo Elastin and the soft food Sofmeat for older people contributed to higher revenue and profit in the Fisheries Food Business. - FY2018-Q2AdvancedAnnual report
「In functional foods, sales volumes of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people increased, resulting in higher revenue. As a result, revenue was ¥2,311 million, up 12.1% year on year, and segment profit (operating profit) was ¥184 million, compared with a loss of ¥16 million in the same period of the previous year.」
Higher sales volumes of Katsuo Elastin and Sofmeat were accompanied by higher revenue in the Fisheries Food Business and a turnaround from a segment loss in the same period of the previous year to profit of ¥184 million. - FY2018-Q1AdvancedAnnual report
「In the Marine Food Business, revenue increased due to higher exports of fish paste products and increased sales volumes of the functional food ingredient bonito elastin and the soft food “Sofmeat” for the elderly. As a result, revenue was ¥1,165 million, up 11.4% year on year, and segment profit (operating profit) was ¥104 million, compared with a loss of ¥10 million in the same period of the previous year.」
Higher sales volumes of Katsuo Elastin and Sofmeat increased revenue, and segment profit in the Fisheries Food Business improved from a loss of ¥10 million in the same period of the previous year to ¥104 million. - FY2017AdvancedAnnual report
「Of the R&D themes, particular emphasis is placed on research and development of functional ingredients derived from natural products. The main initiatives during the fiscal year were in vitro tests, animal studies and human clinical trials to accumulate evidence and present results, as described below. • Elastin Analysis and other work for products compliant with the Foods with Function Claims labeling system Conducting clinical trials to confirm the effects of Katsuo Elastin intake on vascular elasticity and endothelial function」
Research into functional ingredients and evidence accumulation were made concrete through clinical trials of Katsuo Elastin, accumulation of immune-related evidence for Ascophyllan HS, and testing of Hishi extract, among other activities. - FY2017-Q3AdvancedAnnual report
「In the Fisheries Food Business, sales of fish-paste products remained at the previous year's level, but revenue increased as expanded sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people increased new customer relationships. As a result, revenue was ¥3,119 million, up 5.0% year on year, and segment profit (operating profit) was ¥23 million, compared with a loss of ¥50 million in the same period of the previous year.」
Increased new customer relationships from expanded sales of Katsuo Elastin and Sofmeat helped the Fisheries Food Business turn from a loss in the previous year to segment profit of ¥23 million. - FY2017-Q2AdvancedAnnual report
「In functional foods, the Company worked to expand sales of the functional food ingredient Katsuo Elastin and the soft food Sofmeat for older people. Revenue increased as new customer relationships grew.」
Expanded sales of Katsuo Elastin and Sofmeat increased new customer relationships, contributing to higher revenue in the Fisheries Food Business. - FY2017-Q1AdvancedAnnual report
「The Fisheries Food Business posted higher revenue, due in part to strong sales of the functional food ingredient Katsuo Elastin.」
Progress in natural-product-derived functional ingredients included strong sales of Katsuo Elastin and higher revenue in the Fisheries Food Business. - FY2016First statedAnnual report
「Of the R&D themes, particular emphasis is placed on the research and development of functional ingredients derived from natural products. The main initiative during the fiscal year was conducting clinical trials of functional ingredients, as described below.」
Analysis, evidence accumulation and clinical trials are being conducted for elastin, Ascophyllan HS and Hishi extract.